

10/070963

PATENT

JG13 Rec'd PCT/PTO 13 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#7/9/3/02

In re application of: Bischoff, et al.

Serial No.: National Stage Filing of PCT/EP00/08836

Filed: Herewith

For: Novel Combination for the Treatment of Sexual Dysfunction

BOX PCT  
ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

**FEE PAYMENT**


Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 48,972

Telephone: (203) 812-6450

Date: MAR 13 2002

  
Susan M. Pellegrino  
Attorney for Applicant(s)  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516

10/070963  
13 MAR 2002

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Serial No.	Group Art Unit	Filing Date MAR 13 2002	Atty. Docket No. Le A 33 965
INFORMATION DISCLOSURE CITATION				Applicant(s) BISCHOFF, et al.			
U.S. PATENT DOCUMENTS							
*		DOCUMENT NO.	DATE MM/DD/YY	NAME	CLASS	S U B - CLASS	FILING DATE IF APPROPRIATE

	U1	5	0	0	6	5	3	0	04/09/91	Angerbauer et al.	514	277	01/17/89

FOREIGN PATENT DOCUMENTS														
*		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	S U B - CLASS	TRANSLATION	
													YES	NO
	F1	9	9	2	4	4	3	3	20/05/99	WO				X
	F2	9	6	1	6	6	4	4	06/06/96	WO				
	F3	9	4	2	8	9	0	2	22/12/94	WO				
	F4	0	3	2	5	1	3	0	26/07/89	EP			X	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)														
	R2	Cheitlin, M. D., Hutter, A. M., Brindis, R. G., Ganz, P., Kaul, S., Russell, R. O., Zusman, R. M., "Use of Sildenafil (Viagra) in Patients with Cardiovascular Disease", Circulation, 99: 168-177 (1999)												
	R3	Laufs, U., La Fata, V., Plutzky, J., Liao, J. K., "Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors", Circulation, 97: 1129-1135 (1998)												
	R4	Watanabe, M., Koike, H., Ishiba, T., Okada, T., Seo, S., Hirai, K., "Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors", Bioorganic & Medicinal Chemistry, 5(2): 437-444 (1997)												

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	